Browse > Article
http://dx.doi.org/10.4333/KPS.2008.38.3.151

Circadian Changes in the Pharmacokinetics of Acebutolol Orally Administered to Rabbits  

Lee, Chong-Ki (Department of Medical Management, Chodang University)
Choi, Jun-Shik (College of Pharmacy, Chosun University)
Publication Information
Journal of Pharmaceutical Investigation / v.38, no.3, 2008 , pp. 151-155 More about this Journal
Abstract
Circadian variations of acebutolol and its main metabolite, diacetolol pharmacokinetics were studied after a single oral administration of acebutolol (10 mg/kg) to eight rabbits at 10 : 00 AM (in the morning) and 10 : 00 PM (at night). The plasma concentration profiles of acebutolol were significantly different (P<0.05) between 10 : 00 AM and 22 : 00 PM, suggesting circadian variations of pharmacokinetic behaviors. A significant circadian rhythm of pharmacokinetic parameters was noted in rabbits, showing higher total body clearance (CL/F), and lower the area under the plasma concentration-time curves (AUC) of acebutolol than that at night. The half-life ($t_{1/2}$) of acebutolol and diacetolol were also significantly shorter in the morning than at night (P<0.05). Metabolite-parent AUC ratio at night significantly decreased compared to in the morning, implying that night time could inhibit acebutolol metabolism than in the morning. From this study there was an administration-time difference of acebutolol pharmacokinetics in the rabbits. The optimized dosing regimen of acebutolol can be decided by considering circadian rhythm so that the effective therapies are established for patients.
Keywords
Acebutolol; Diacetolol Pharmacokinetics; Circadian rhythm; Dosing regimen;
Citations & Related Records
연도 인용수 순위
  • Reference
1 M.H. Smolensky and G. Labrecque, Chronotherapeutics, Pharm. News., 4, 1016 (1997)
2 J. Clench, A. Reinberg and Z. Dziewanowska, Cancadian changes in the bioavailability and effect of indomethacin in healthy subject, Eur. J. Clin. Pharmacol., 20, 359369 (1981)
3 J.N. Buskin, R.A. Upton, R. Jones and R.L. Williams, High performance liquid chromatography assay of acebutolol and its metabolites in plasma and urine, J. Chromatogr., 230, 438-442 (1982)   DOI   ScienceOn
4 K. Yamaoka, Y. Tanigawara, T. Nakagawa and T. Uno, A pharmacokinetics analysis program for microcomputer, J. Pharm. Dyn., 4, 879-883 (1971)
5 B. Lemmer, The chronopharmacology of cardiovascular medications, Ann. Rev Chronopharmacol., 2, 199-228 (1986)
6 B. Lemmer and G. Labrecque, Chronopharmacology and chronotherapeutics: Definitions and concepts, Chronobiol. Int., 4, 319-329 (1987)   DOI   ScienceOn
7 B. Lemmer and K. Bathe, Stereospecific and circadian-phasedependent kinetic behavior of propranolol in plasma, heart, and brain of light--dark-synchronized rats, J. Cardiovasc. Pharmacol., 4, 635-44 (1982)   DOI   ScienceOn
8 B. Lemmer, K. Bathe, P.H. Lang and G. Neumann and H. Winkler, Chronopharmacology of beta-adrenergic blocking drugs: Pharmacokinetics and pharmacodynamic studies, J. Am. Coll. Toxicol., 2, 347-357 (1983)   DOI
9 A. Markiewicz and K. Semenowicz, Time dependent changes in the pharmacokinetics of aspirin, J. Clin. Pharmacol. Biopharm., 32, 330339 (1982)
10 U. Klotz and G. Ziegler, Physiologic and temporal variation in hepatic elimination of midazolam, Clin. Pharmacol. Ther., 32, 107-112 (1982)   DOI   ScienceOn
11 S. Nakano and I.E. Hollister, No circadian effect on nortriptyline kinetics in man, Clin. Pharmacol. Ther., 23, 199-203 (1978)   DOI
12 L. Lamberg, Chronotherapeutics: Implication for drug therapy, American Pharmacy., 31, 2023 (1991)
13 A.A. Gulaid, I.M. James and C. . Kaye, The Pharmacokinetics of acebutolol in man, following the oral administration of acebutolol as a single dose and during and after repeated oral dosing, Biopharm. Drug Dispos., 2, 103-114 (1981)   DOI   ScienceOn
14 R. Gabriel, C.M. Kaye and M.G. Sankey, Preliminary observations on the excretion of acebutolol and its acetyl matabolite in the urine and feces of man, J. Pharm. Pharmacol., 33, 386- 387 (1981)   DOI
15 B. Lemmer, Circadian rhythm and drug delivery, J. Contr. Rel., 16, 6374 (1991)
16 B. Lemmer, Chronophamacological aspects of PK/PD modeling, Int. J. Clin. Ther., 35, 458464 (1977)
17 G. Labrecque, D. Beauchamp, M. Vanier and M.H. Smolensky, Chronopharmacokinetics, Pharm. News., 4, 1721 (1997)
18 W.J.M. Hrushesky, R. Borch and F. Levi, Circadian time dependence in cisplastin urinary kinetics, Clin. Pharmacol. Ther., 32, 330339 (1982)
19 P.M. Belanger, Drug metabolism, Pharm. News., 4, 2226 (1997)
20 T.L. Holcslaw, T.S. Miya and W.S. Bousqut, Circadian rhythm in drug action and drug metabolism in the mouse, J. Pharmacol. Exp. Ther., 195, 320332 (1975)
21 J.S. Choi and H.J. Park, Circadian changes in pharmacokinetics of cyclosporin in healthy volunteers, Res. Commun. Mol. Pathol. Pharmacol., 103, 109112 (1999)
22 G.M. Kyle, K. Smolensky, J. Korczynska and J.P. Mcgoven, In recent advances in the chronobiology of allergy and immunology, M.H. Smolensky, ed, Pergamon Press. Oxford., 123- 128 (1980)
23 P. Loiseau, B. Cenraud, R.H. Levy and R. Akbaraly, Diurnal variations in steady-state plasma concentration of valproic acid in epiletic patients, Clin. Pharmacokinet., 7, 544552 (1982)
24 J.S. Choi, C.K. Kim and B.J. Lee, Administration-time differences in the pharmacokinetics of gentamycin intravenously delivered to human beings, Chlono. Inter., 16, 821829 (1999)
25 G.L. Mattok and J. Mcgilveray, The effect of food intake and sleep on absorption of acetaminophen, Rev. Can. Biol., 32, 7784 (1973)
26 B. Langner and B. Lemmer, Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects, Eur. J. Clin. Pharmacol., 33, 619-624 (1988)   DOI
27 A. Fujimura, Y. Kumagai, K. Sugimoto, H. Nakashima, H. Kajiyama, A. Ebihara and K. Ohashi, Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects, Eur. J. Clin. Pharmacol., 38, 133-137 (1990)
28 J.S. Choi, S.C. Shin and J.P. Burm, Circadian changes in the pharmacokinetics of triamcinolone acetonide in rabbits, Res. Commun. Mol. Pathol. Pharmacol., 107, 233238 (2000)
29 F. Alhenz-Gelas, P.F. Plouin, M.B. Ducrocq, P.E. Corvol and J. Menard, Comparison of the antihypertensive and hormonal effects of a cardioselective beta-blocker acebutolol and diuretics in essential hypertension, Am. J. Med., 64, 1005-1012 (1978)   DOI   ScienceOn
30 E.S. Vessel, C.A. Shively and G.T. Passananti, Temporal variation of antipyrine half-life in man, Clin. Pharmacol. Ther., 22, 843-852 (1977)   DOI
31 M.A. Martin, C.A. Phillips and A.J. Smith, Acebutolol in hypertension a double blind trial against placebo, Br. J. Clin. Pharmcol., 6, 351-356 (1978)   DOI   ScienceOn
32 P.G. Baker and J.A. Goulton, Multicentre study of a once daily dosage of acebutolol in the treatment of hypertension in general practice, J. Int. Med. Res., 7, 201-214 (1979)   DOI
33 A. Roux, B. Flouvat, N. P. Chau, B. Letac and B. Lucsko, Pharmacokinetics of acebutolol after intravenous bolus administration, Br. J. Clin. Pharmacol., 9, 215-217 (1980)   DOI   ScienceOn
34 A.J. Mclean, R.J. Mcnamara, P.D. Souich, M. Gibaldi and D. Lalka, Food, splanchnic blood flow and bioavailability of drugs subject to first pass metabolism, Clin. Pharmacol. Ther., 24, 510 (1978)
35 J. Basil and R. Jordan, Pharmacological properties of diacetolol, a major metabolite of acebutolol, Eur. J. Pharmacol., 80, 47-56 (1982)   DOI   ScienceOn
36 B. Flouvat, A. Roux and N.P. Chau, Pharmacokinetics and bioavailability of diacetolol, the main matabolite of acebutolol, Eur. J. Clin. Pharmacol., 19, 287-292 (1981)   DOI
37 C.F. George and B.S. Gruchy, Elimination of drugs by active intestinal transport, J. Pharm. Pharmacol., 31, 643-644 (1979)   DOI